Dr. Sara Rogers is a Clinical Assistant Professor with joint appointments at the Institute of Biosciences and Technology and the School of Engineering Medicine at Texas A&M University. She directs the clinical pharmacogenomics service at Texas A&M Health, where she leads initiatives to integrate pharmacogenetics into clinical care through decision support tools, implementation strategies, and stakeholder-informed policy. Dr. Rogers co-founded the American Society of Pharmacovigilance and co-leads the STRIPE Collaborative Community, an FDA-supported initiative to establish national standards for pharmacogenetics testing. She also serves as Chair of the U.S. Pharmacopeia (USP) Personalized Medicine Expert Committee and is a member of USP’s Council of Experts, which provides scientific and policy leadership for the development of quality standards for medicines and other healthcare products. Her research leverages digital health innovation, implementation science, and community-engaged approaches to advance safe, equitable, and personalized medication use at scale.
Research Interests
Development of Community-Informed Health Policies Informed by Ethical Values and Priorities
Advancement of Medication and Genetics Literacy Among Underserved Populations and Frontline Clinicians
Discovery of Novel Genetic Associations that Influence Medication Response
Design and Implementation of Clinical Decision Support Tools to Enable Genetics-Informed Prescribing
Development and Promotion of Consensus-Based Industry Standards for Pharmacogenetics Testing
Evaluation of Precision Medicine Implementation Strategies to Inform Equitable Health Policy
Publications
Evaluation of gaps in direct oral anticoagulants (DOACs) management in an outpatient underserved clinic: a cross-sectional study. Sci Rep. 2025;15(1):23064. Published 2025 Jul 2. doi:10.1038/s41598-025-07712-0
Implementation and integration of a multidisciplinary pharmacogenomics service in an underserved integrated behavioral health clinic. Front Pharmacol. 2025;16:1594032. Published 2025 May 22. doi:10.3389/fphar.2025.1594032
Medical policy determinations for pharmacogenetic tests among US health plans. Am J Manag Care. 2025;31(2):e47-e55. Published 2025 Feb 1. doi:10.37765/ajmc.2025.89683
Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. Am J Health Syst Pharm. 2024;81(16):672-683. doi:10.1093/ajhp/zxae110
Case Report: Life-Threatening Fluoxetine-Linked Postoperative Bleeding Informed by Pharmacogenetic Evaluation. Drugs R D. 2024;24(1):117-121. doi:10.1007/s40268-023-00451-5
Application of the community dialogues method to identify ethical values and priorities related to pharmacogenomics. Pharmacogenomics. 2021;22(11):693-701. doi:10.2217/pgs-2021-0017
PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing. Pharmacogenomics. 2020;21(11):785-796. doi:10.2217/pgs-2019-0192
Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Pharmacogenomics. 2018;19(14):1089-1093. doi:10.2217/pgs-2018-0115